When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Last reviewed: 18 Mar 2025
Last updated: 28 Feb 2025

Summary

Definition

History and exam

Key diagnostic factors

  • presence of risk factors
  • erythema and/or ulceration of oral mucosa
  • oral pain

Other diagnostic factors

  • intra-oral bleeding
  • dietary impairment and/or weight loss
  • diarrhoea
  • nausea and/or vomiting
  • abdominal pain
  • fever

Risk factors

  • intensive chemotherapy regimens
  • radiotherapy to the oral cavity
  • chemoradiation
  • genetic polymorphisms in drug metabolic enzymes
  • use of targeted therapies and immunotherapies

Diagnostic investigations

Investigations to consider

  • FBC with differential
  • blood cultures
  • superficial smear of lesion for microscopy
  • fungal culture
  • viral culture or polymerase chain reaction (PCR)

Treatment algorithm

Contributors

Authors

Ourania Nicolatou-Galitis, DDS, MSc, DrDent

Dentist

Specialist in Oral Medicine and Oral Oncology

Hospital Dentistry

National & Kapodistrian University of Athens

Athens

Greece

Disclosures

ONG has received fees from Angelini pharma to author a review article on oral mucositis and is the co-founder and scientific responsible of mycancer, a startup private company which aims to provide a comprehensive medical platform for cancer patients. ONG is an author of several references cited in this topic.

Nikolaos Tsoukalas, MD, MSc, PhD

Medical Oncologist

Associate Director

Department of Oncology

401 General Military Hospital

Athens

Greece

Disclosures

NT declares that he has no competing interests.

Acknowledgements

Professor Ourania Nicolatou-Galitis and Dr Nikolaos Tsoukalas would like to gratefully acknowledge Dr Eleni Arvanitou, who contributed to the updating of this topic, and Dr Rajesh V. Lalla, a previous contributor.

Disclosures

EA declares that she has no competing interests. RVL serves as a consultant for Galera Therapeutics, Ingalfarma, Mundipharma and Sucampo Pharma, and has received research funding from Onxeo, Sucampo Pharma, Galera Therapeutics, and Novartis.

Peer reviewers

Michael Brennan, DDS, MHS

Associate Chairman and Oral Medicine Residency Director

Department of Oral Medicine

Carolinas Medical Center

Charlotte

NC

Disclosures

MB is an author of a reference cited in this topic. MB is part of the Mucositis Study Group of MASCC/ISOO, and participated in the review of mucositis.

Maria Michelagnoli, MB ChB, MD, FRCPCH

Consultant Pediatric and Adolescent Oncologist

University College London Hospitals

London

UK

Disclosures

MM declares that she has no competing interests.

Use of this content is subject to our disclaimer